ARQT - Is Now the Time to Bet on Arcutis Biotherapeutics?
More than 7.4 million people in the U.S. and 125 million worldwide suffer from psoriasis, an autoimmune disease of varying severity that often leads to red patchy skin on the elbows, knees, scalp, and elsewhere on the body. Its cause is unknown, and so far, no cures have been discovered -- only treatments.
Arcutis Biotherapeutics (NASDAQ: ARQT) focuses on developing treatments for dermatological diseases and conditions such as psoriasis. With one phase 3 clinical trial of a formulation of its lead candidate just getting under way and another for a different formulation nearing completion, the company hopes to soon provide sufferers with alternative treatments for their itchy, irritated skin. But does the current situation also provide a smart buying opportunity for investors?
Image Source: Getty Images
For further details see:
Is Now the Time to Bet on Arcutis Biotherapeutics?